Enhanced anti-tumor effects with microencapsulated c-myc antisense oligonucleotide.

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Antisense oligonucleotides offer targeted gene silencing for cancer therapy.
• Conventional delivery methods for oligonucleotides can limit their therapeutic potential.
• Developing effective delivery systems is crucial for enhancing oligonucleotide efficacy.

Purpose of the Study:

• To evaluate the therapeutic efficacy of a novel formulation of c-myc antisense oligonucleotide encapsulated in biodegradable microspheres.
• To compare the efficacy of this microencapsulated formulation with intravenous administration of the unencapsulated drug.
• To assess the impact of sustained-release delivery on tumor growth, metastasis, and survival in xenograft models.

Main Methods:

• A phosphorothioate c-myc antisense oligonucleotide was complexed with zinc and encapsulated into injectable biodegradable microspheres.
• The microencapsulated formulation and unencapsulated drug were administered intravenously to immunocompromised mice bearing human melanoma and leukemia xenografts.
• Tumor growth, number of metastases, c-myc gene expression, and animal survival were monitored and compared between treatment groups.

Main Results:

• The microencapsulated formulation demonstrated superior efficacy in both melanoma and leukemia xenografts.
• Significant reductions in tumor growth, decreased metastasis, and lower c-myc expression were observed with the microsphere formulation in the melanoma model.
• The leukemia model showed decreased metastatic potential and increased survival rates with the microencapsulated drug.
• Overall survival was improved in both models when using the sustained-release formulation.

Conclusions:

• Injectable biodegradable microspheres represent a promising sustained-release delivery system for c-myc antisense oligonucleotides.
• This novel formulation significantly enhances the therapeutic efficacy of antisense oligonucleotides in preclinical cancer models.
• Sustained-release delivery of antisense oligonucleotides can overcome limitations of conventional administration, leading to improved treatment outcomes.